nach oben

Erschienen in:

24.01.2017 | Original Article

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus

verfasst von: Fatemeh Fotouhi, Mina Shaffifar, Behrokh Farahmand, Sadegh Shirian, Mohsen Saeidi, Alijan Tabarraei, Ali Gorji, Amir Ghaemi

Erschienen in: Archives of Virology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

DNA vaccines can induce both humoral and cellular immune responses in animals. However, DNA vaccines suffer from limited vaccine potency due to low immunogenicity. Therefore, different strategies are required for significant improvement of DNA vaccine efficacy such as inclusion of strong adjuvants. The aim of the present study was to investigate the effects of using α-Galactosylceramide (α-GalCer) as an adjuvant to enhance the immune responses induced by a DNA vaccine, encoding influenza A virus matrix protein 2 (M2), against influenza A challenge. BALB/c mice were immunized three times by intramuscular inoculations of DNA vaccine encoding M2 alone or in combination with α-GalCer adjuvant. The adjuvant effect was evaluated by measuring the serum antibody titers, using ELISA, lymphocyte proliferation, using MTT assay as well as Th1 (IFN-γ and IL-12) and Th2 (IL-4) cytokines. The results showed that co-administration of α-GalCer with the vaccine exert protective effects by influencing the magnitude and quality of humoral responses. Adjuvanted DNA-vaccinated mice revealed a higher IgG titer and IgG2a/IgG1 ratio than mice vaccinated with DNA alone. Furthermore, analysis of M2-specific responses revealed that the DNA vaccine triggered predominately IgG1 and IL-4 responses indicating a Th2 bias. The data also showed that α-GalCer is a potent adjuvant for activation of cellular immune responses to DNA vaccine. This was supported by a higher IgG2a/IgG1 ratio, significantly increased IFN-γ and IL-4 production and CD4+ proliferation, compared with mice receiving the DNA vaccine alone, suggesting a mixed Th1/Th2-type cellular immune response with a Th1 bias. The findings of this study indicate that α-GalCer has the potential to be used as a potent adjuvant for a DNA vaccine encoding M2, since it enhances humoral and cellular immune response and improves immune protection against influenza challenge in mice.

Andersson A-MC, Håkansson KO, Jensen BAH, Christensen D, Andersen P, Thomsen AR, Christensen JP (2012) Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PloS One 7:e46395CrossRefPubMedPubMedCentral

Artiaga BL, Yang G, Hackmann TJ, Liu Q, Richt JA, Salek-Ardakani S, Castleman WL, Lednicky JA, Driver JP (2016) α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. Sci Rep 6:23593. doi:10.1038/srep23593

Bandyopadhyay K, Marrero I, Kumar V (2016) NKT cell subsets as key participants in liver physiology and pathology. Cell Mol Immunol 13:337–346CrossRefPubMedPubMedCentral

Brown LE, Kelso A (2009) Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 87:300–308CrossRefPubMed

Carnaud C, Lee D, Donnars O, Park S-H, Beavis A, Koezuka Y, Bendelac A (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:4647–4650PubMed

Cerundolo V, Silk JD, Masri SH, Salio M (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9:28–38CrossRefPubMed

Chackerian A, Alt J, Perera V, Behar SM (2002) Activation of NKT cells protects mice from tuberculosis. Infect Immun 70:6302–6309CrossRefPubMedPubMedCentral

Chen H, Angel M, Li W, Finch C, Gonzalez AS, Sutton T, Santos J, Perez DR (2014) All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines. J Virol 88:10013–10025CrossRefPubMedPubMedCentral

Chen Q, Mosovsky KL, Ross AC (2011) Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo. Clin Vaccine Immunol 18:1015–1020CrossRefPubMedPubMedCentral

10.

Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng P-Y, Bandaranayake D, Breiman RF, Brooks WA, Buchy P (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12:687–695CrossRefPubMed

11.

De Santo C, Salio M, Masri SH, Lee LY, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, Grone HJ, Platt FM, Zambon M, Cerundolo V (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Investig 118:4036–4048CrossRefPubMedPubMedCentral

12.

Deng L, Cho KJ, Fiers W, Saelens X (2015) M2e-based universal influenza A vaccines. Vaccines 3:105–136CrossRefPubMedPubMedCentral

13.

Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3395–3403CrossRefPubMed

14.

Duan S, Thomas PG (2016) Balancing immune protection and immune pathology by CD8+T-cell responses to influenza infection. Front Immunol 7:25. doi:10.3389/fimmu.2016.00025

15.

Dwivedi V, Manickam C, Dhakal S, Binjawadagi B, Ouyang K, Hiremath J, Khatri M, Hague JG, Lee CW, Renukaradhya GJ (2016) Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs. Vet Microbiol 186:157–163CrossRefPubMed

16.

Exley MA (2012) Editorial: NKT get the ‘flu: NKT cells as (mostly) good guys in influenza; monocytic cells as double agents. J Leukoc Biol 91:349–352CrossRefPubMed

17.

Fischer WA, II MG, Bhagwanjee S, Sevransky J (2014) Global burden of influenza: contributions from resource limited and low-income settings. Glob Heart 9:325CrossRefPubMedPubMedCentral

18.

Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A (2016) Combination of the toll like receptor agonist and alpha-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci 23:16CrossRefPubMedPubMedCentral

19.

Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M (2007) Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis 30:197–210CrossRefPubMed

20.

Guillonneau C, Mintern JD, Hubert F-X, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ (2009) Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci 106:3330–3335CrossRefPubMedPubMedCentral

21.

Hemann EA, Kang SM, Legge KL (2013) Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol (Baltimore, Md: 1950) 191:2486–2494CrossRef

22.

Holvast A, De Haan A, Van Assen S, Stegeman CA, Huitema MG, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J (2010) Cell-mediated immune responses to influenza vaccination in Wegener’s granulomatosis. Ann Rheum Dis 69:924–927CrossRefPubMed

23.

Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD (2008) Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26:1807–1816CrossRefPubMed

24.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201–214CrossRefPubMed

25.

Hung J-T, Tsai Y-C, Lin W-D, Jan J-T, Lin K-H, Huang J-R, Cheng J-Y, Chen M-W, Wong C-H, Alice LY (2014) Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antivir Res 107:110–118CrossRefPubMed

26.

Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, Jerud ES, Goldberg MF, Baena A, Karl O (2009) Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30:888–898CrossRefPubMedPubMedCentral

27.

Iwasaki A, Pillai PS (2014) Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328CrossRefPubMedPubMedCentral

28.

Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T (2008) Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1:208–218CrossRefPubMed

29.

Kim M-C, Song J-M, Eunju O, Kwon Y-M, Lee Y-J, Compans RW, Kang S-M (2013) Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 21:485–492CrossRef

30.

Ko S-Y, Ko H-J, Chang W-S, Park S-H, Kweon M-N, Kang C-Y (2005) α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175:3309–3317CrossRefPubMed

31.

Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P (2009) Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27:3766–3774CrossRefPubMedPubMedCentral

32.

Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776–788CrossRefPubMedPubMedCentral

33.

Mohan T, Verma P, Rao DN (2013) Novel adjuvants and delivery vehicles for vaccines development: a road ahead. Indian J Med Res 138:779PubMedPubMedCentral

34.

Monto AS (2004) Global burden of influenza: what we know and what we need to know. In: International Congress Series. Elsevier, pp 3–11

35.

Naderi M, Saeedi A, Moradi A, Kleshadi M, Zolfaghari MR, Gorji A, Ghaemi A (2013) Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin 28:167–173CrossRefPubMed

36.

Reed LJMH (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497

37.

Robertson FC, Berzofsky JA, Terabe M (2014) NKT cell networks in the regulation of tumor immunity. Front Immunol 5:543CrossRefPubMedPubMedCentral

38.

Saeedi A, Ghaemi A, Tabarraei A, Moradi A, Gorji A, Semnani S, Soleimanjahi H, Adli AH, Hosseini SY, Vakili MA (2014) Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice. Virus Genes 49:11–21CrossRefPubMed

39.

Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A (2014) Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol 159:1951–1960CrossRefPubMed

40.

Scorza FB, Tsvetnitsky V, Donnelly JJ (2016) Universal influenza vaccines: shifting to better vaccines. Vaccine 34:2926–2933CrossRef

41.

Shang L, Liu Q, Liu W, Men J, Gao S, Jiang L, Wang Z, Zhai Y, Jin H, Lian H, Chen C, Xia Z, Yuan Z, Zhu XQ (2009) Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge. Vaccine 27:2741–2745CrossRefPubMed

42.

Sridhar S (2016) Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines. Front Immunol 7:195. doi:10.3389/fimmu.2016.00195

43.

Stanekova Z, Vareckova E (2010) Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 7:351CrossRefPubMedPubMedCentral

44.

Sullivan BA, Kronenberg M (2005) Activation or anergy: NKT cells are stunned by α-galactosylceramide. J Clin Investig 115:2328–2329CrossRefPubMedPubMedCentral

45.

Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F, Kelishadi M (2014) Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci 21:69CrossRefPubMedPubMedCentral

46.

Tau GZ, Cowan SN, Weisburg J, Braunstein NS, Rothman PB (2001) Regulation of IFN-γ signaling is essential for the cytotoxic activity of CD8+T cells. J Immunol 167:5574–5582CrossRefPubMedPubMedCentral

47.

Van Kaer L, Parekh VV, Wu L (2011) Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 3:59–75CrossRefPubMed

48.

Xu K, Ling Z-Y, Sun L, Xu Y, Bian C, He Y, Lu W, Chen Z, Sun B (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 24:45–56CrossRefPubMedPubMedCentral

Titel: Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus
verfasst von: Fatemeh Fotouhi
Mina Shaffifar
Behrokh Farahmand
Sadegh Shirian
Mohsen Saeidi
Alijan Tabarraei
Ali Gorji
Amir Ghaemi
Publikationsdatum: 24.01.2017
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 5/2017
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-017-3230-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Molecular characterisation of fowl adenovirus type 7 isolated from poultry associated with inclusion body hepatitis in Poland

Effect of porcine circovirus type 2 (PCV2) on the function of splenic CD11c+ dendritic cells in mice

Antigenic and genotypic characterization of rabies virus isolated from bats (Mammalia: Chiroptera) from municipalities in São Paulo State, Southeastern Brazil

A highly divergent Puumala virus lineage in southern Poland

50 years of the International Committee on Taxonomy of Viruses: progress and prospects

Molecular characterization of a novel reassortant H7N6 subtype avian influenza virus from poultry in Eastern China, in 2016

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin